Friday - April 18, 2025
ST. PAUL, Minn., Feb. 5, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) Solventum today announced that its AI-powered radiology speech reporting solution, Solventum™ Fluency™ for Imaging, has ranked #1 in the 2025 Best in KLAS Awards—Software and Services Report for the fifth time.
Enabling faster, more accurate documentation, Solventum Fluency for Imaging helps radiologists save time, reduce burnout and improve efficiency by streamlining the reporting process. The technology integrates seamlessly into radiology workflows and allows for quicker, more precise report creation while minimizing administrative tasks and rework. This empowers radiologists to focus on what matters most—delivering high quality patient care.
"We've been using Solventum's radiology solution for more than a decade and benefited from both its exceptional voice recognition accuracy and continuous reliability," said Dr. Charles Q. Li, neuroradiologist and IT officer at the Allegheny Health Network. "This technology has helped to unburden our radiologists from repetitive and clerical activities, enhancing our efficiency and job satisfaction. It's no wonder Solventum continues to be an industry standard to which other reporting solutions are compared."
The annual report, conducted by KLAS Reseach, recognizes software and services companies that are committed to helping healthcare professionals deliver better patient care. Based solely on customer feedback collected via confidential interviews and product evaluations over a one-year period, winning the award signifies top performing solutions that go above and beyond in six key pillars: value, product, loyalty, relationship, operations and culture.
"As radiology practices face the challenge of delivering high quality care while controlling costs, we're proud that our technology plays a powerful role in helping radiologists more effectively and efficiently tackle their overwhelming workloads," said Garri Garrison, president, Health Information Systems, Solventum. "We are honored to receive this recognition from KLAS and thank our customers for their ongoing trust and partnership."
About Solventum
At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.
About KLAS
KLAS is a research and insights firm on a global mission to improve healthcare. Working with thousands of healthcare professionals and clinicians, KLAS gathers data and insights on software and services to deliver timely reports and performance data that represent provider and payer voices and act as catalysts for improving vendor performance. The KLAS research team publishes reports covering the most pressing questions facing healthcare technology today, including emerging technology insights, that provide early insights on the future of healthcare technology solutions. KLAS also fosters measurement and collaboration between healthcare providers and payers and best practice adoption. Learn more at klasresearch.com.
Last Trade: | US$66.26 |
Daily Change: | 0.59 0.90 |
Daily Volume: | 897,516 |
Market Cap: | US$11.450B |
March 12, 2025 February 27, 2025 November 14, 2024 November 07, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load